

24 June 2024

Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%	
1. To receive the Company's annual report and accounts for the year ended 31 December 2023	75,934,412	93.27	5,924,896	6.73	2
2. To approve the Directors' Remuneration Report	75,900,186	93.23	5,924,896	6.77	10
3. To re-appoint John Michael Treacy as a Director of the Company	74,370,196	91.35	5,924,896	8.65	2
4. To re-appoint Dawn Coverly as a Director of the Company	75,700,196	92.98	5,924,896	7.02	0
5. To re-appoint Nigel Ronald Lee as a Director of the Company	75,734,386	93.03	5,924,896	6.97	2
6. To re-appoint PKF Littlejohn LLP as auditor of the Company	75,734,398	93.03	5,924,896	6.97	0
7. To authorise the Directors to determine the auditor's remuneration	75,734,396	93.03	5,924,896	6.97	2
8. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company	72,596,681	89.17	5,924,896	10.83	0
9. Authorise the Directors to allot equity securities disapplying pre-emption	73,960,822	90.92	6,175,857	9.08	63,555

rights					
10. That General Meetings may be called on not less than 14 days' notice	67,739,369	92.52	6,175,857	7.48	8,195,045

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale/George Payne (Corporate Finance)
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSEFFLELSELM